Recombinant Human ACE2 / ACEH Protein, Fc Tag (MALS verified), 50µg

Background
Angiotensin-converting enzyme 2 (ACE2) is also known as ACEH (ACE homolog), is an integral membrane protein with considerable homologous to ACE, which belongs to the peptidase M2 family. ACE2 is an exopeptidase that catalyses the conversion of angiotensin I to the nonapeptide angiotensin, or the conversion of angiotensin II to angiotensin 1-7. ACE2 may be an important regulator of heart function. In case of human coronaviruses SARS and HCoV-NL63 infections, ACE-2 serve as functional receptor for the spike glycoprotein of both coronaviruses. ACE2 is activated by chloride and fluoride, but not bromide and Inhibited by MLN-4760, cFP_Leu, and EDTA, but not by the ACE inhibitors linosipril, captopril and enalaprilat. ACE2 is active from pH 6 to 9, and the optimum pH is 6.5 in the presence of 1 M NaCl.

Source
Recombinant Human ACE2, Fc Tag (MALS verified) (AC2-H5257) is expressed from human 293 cells (HEK293). It contains AA Gln 18 - Ser 740 (Accession # Q9BYF1-1).Predicted N-terminus: Gln 18

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus. The protein has a calculated MW of 110.0 kDa. The protein migrates as 125-150 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, Arginine, pH7.5. Normally glycerol is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Bioactivity
Please refer to product data sheet.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70^°C for 12 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Serum proteomic profiling of rheumatoid arthritis-interstitial lung disease with a comparison to idiopathic pulmonary fibrosis"
Wu, Jeong, Poli de Frías et al
Thorax (2022)
(2) "Impact of COVID-19 on male urogenital health: success of vaccines"
Kucukyildiz, Yilmaz-Oral, Turkcan et al
Drug Discov Today (2022)
(3) "Mitigation of Multi-Organ Radiation Injury with ACE2 Agonist Diminazene Aceturate"
Gasperetti, Sharma, Frei et al
Radiat Res (2022)
Showing 1-3 of 9887 papers.

Citations

(1) "Track-etched membrane microplate and smartphone immunosensing for SARS-CoV-2 neutralizing antibody"
Authors: Wang C, Wu Z, Liu B, et al.
Journal: Biosens Bioelectron 2021
Application: Binding Assay
(2) "A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency"
Authors: Leach A, Ilca FT, Akbar Z, et al.
Journal: Antiviral research 2021
Application: Binding Assay
(3) "Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents"
Authors: Mei, Jie et al.
Journal: Journal of ethnopharmacology 2021
Application: SPR
(4) "SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity"
Authors: Ozono S, Zhang Y, Ode H, et al.
Journal: Nature communications 2021
Application: BLI
(5) "SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination"
Authors: Huang WC, Zhou S, He X, et al.
Journal: Advanced materials 2020
Application: Binding Assay
(6) "Plasma-activated water: An alternative disinfectant for S protein inactivation to prevent SARS-CoV-2 infection"
Authors: Guo L, Yao Z, Yang L, et al.
Journal: Chemical engineering journal 2020
Application: SPR & ELISA